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ABSTRACT 
Cardiovascular (CV) comorbidities are common in people with epilepsy. Several mechanisms 
explain why these conditions tend to co-exist including causal associations, shared risk 
factors and those resulting from epilepsy or its treatment  
Various arrhythmias occurring during and after seizures have been described. Ictal asystole is 
the most common cause. The converse phenomenon, arrhythmias causing seizures, appears 
extremely rare and has only been reported in children following cardioinihibitory syncope. 
Arrhythmias in epilepsy may not only result from seizure activity but also from a shared 
genetic susceptibility. Various cardiac and epilepsy genes could be implicated but firm 
evidence is still lacking. Several antiepileptic drugs (AEDs) triggering conduction 
abnormalities can also explain the co-existence of arrhythmias in epilepsy.  
Epidemiological studies have consistently shown that people with epilepsy have a higher 
prevalence of structural cardiac disease and a poorer CV risk profile than those without 
epilepsy. Shared CV risk factors, genetics and etiological factors can account for a significant 
part of the relationship between epilepsy and structural cardiac disease. Seizure activity may 
cause transient myocardial ischaemia and the Takotsubo syndrome. Additionally, certain 
AEDs may themselves negatively affect CV risk profile in epilepsy.  
Here we discuss the fascinating borderland of epilepsy and cardiovascular conditions. The 
review focuses on epidemiology, clinical presentations and possible mechanisms for shared 
pathophysiology. It concludes with a discussion of future developments and a call for 
validated screening instruments and guidelines aiding the early identification and treatment 
of CV comorbidity in epilepsy. 
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INTRODUCTION  
Well over 100 years ago, the occurrence of asystole during the course of an epileptic seizure 
was described: “He uttered a cry and was seen to be rubbing his hands together. His pulse 
was immediately examined for but was not palpable” [1]. Since then numerous associations 
between epilepsy and CV conditions have been identified, including this classical example of 
ictal asystole.  
Co-existing conditions form an important part of the overall burden of epilepsy [2-5]. Several 
mechanisms of association between epilepsy and comorbid conditions have been described: 
associations can be explained by cause or effect, a shared risk factor may cause both 
conditions, or the mechanism of the association is unknown or spurious (i.e. coincidental) 
(Figure 1) [3, 5].  
This review serves to discuss the fascinating borderland between epileptology and 
cardiology and focuses on the major developments over the last 25 years and on future 
developments. We use the comorbidity framework (Figure 1) [3] to review all cardiac 
conditions known, and alleged, to be linked to epilepsy. Associations with cardiac 
arrhythmias are discussed first, followed by an overview of all structural cardiac conditions 
related to epilepsy.  
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Figure 1. Mechanisms of association between epilepsy and comorbid conditions. Figure originates 
from Gaitatzis et al., 2012 [3]. 
EPILEPSY AND CARDIAC ARRHYTHMIAS  
Various arrhythmias have been described, occurring during (ictal) or after (postictal) 
seizures. Sinus tachycardia is the most common ictal pattern, seen in up to 80% of all 
seizures [6] and in 82% of people with epilepsy [7], but usually without symptoms. The most 
frequent clinically relevant arrhythmia is ictal asystole, occurring in 0.318% (95% CI 0.316% 
to 0.320%) of people with refractory focal epilepsy admitted for video-EEG [8]. Ictal asystole, 
bradycardia and AV block predominantly occur in people with temporal lobe epilepsy (Table 
1) [8]. Clinically, ictal asystole is characterised by sudden loss of tone during a dyscognitive 
seizure [9]. The circulatory pattern resembles vasovagal syncope with a transient, 
progressive and self-limiting slowing of the heart rate and decrease of blood pressure [9-11]. 
For many years, ictal asystole was thought to be a possible mechanism underlying sudden 
unexpected death in epilepsy (SUDEP). This appears to be unlikely: all but one reported case 
so far of ictal asystole were self-limiting [8]. In this one case successful resuscitation was 
started after 44 seconds of asystole and the event was classified as near-SUDEP [12]. The 
longest ictal asystole reported so far, however, lasted 96 seconds and appeared self-limiting 
[13]. Whether an event is classified as near-SUDEP or not will depend on interventions of 
medical personnel: prompt resuscitation in response to ictal asystole will likely lead to more 
classified as near-SUDEP cases. While there are no reports of fatal ictal asystole, it remains 
debatable whether ictal asystole can cause SUDEP.  
The precise mechanism of ictal asystole is unknown. It may result from epileptic activity 
directly stimulating the central autonomic networks [6, 14]. For example, focal stimulation of 
parts of the limbic system (i.e. amygdala, cingulate gyrus) may provoke asystole [6, 15-17]. 
Alternatively, seizure-induced fear and catecholamine release [18] may evoke a vasovagal 
response causing cardioinhibition and vasodilation [19]. 
Ictal asystole is assumed to be self-limiting, but may cause falls and injuries due to seizure-
induced syncope [20]. Proper trials are lacking but retrospective studies suggest that 
improving seizure control may prevent ictal asystole [21-23]. It also seems advisable to 
withdraw negative inotropic drugs and to consider the implantation of a loop recorder to 
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monitor possible future events in individuals in whom ictal asystole has been noted. If the 
asystolic episodes persist, cardiac pacemaker implantation should be considered to reduce 
the risk of trauma [20, 21, 23, 24]. 
In contrast to ictal asystole, postictal asystole is less common, associated with convulsive 
rather than focal (temporal lobe) seizures and has a higher fatality rate: 7 of 13 reported 
postictal asystole cases died from SUDEP [8]. All fatal cases had a convulsive seizure with 
immediate postictal generalised EEG suppression and a stuttering course of transient apnoea 
and asystole resulting in a terminal apnoea followed by a terminal asystole [25]. 
The mechanism underlying this sequence of postictal EEG suppression, apnoea, and terminal 
asystole has not yet been elucidated. Excessive inhibition causing brainstem depression 
might play a role [26]. Recent work in two animal models (mice carrying mutations in the 
KCNA1 gene or the SCN1A gene) demonstrated that seizures initiated by direct cortical 
stimulation may evoke a spreading depression causing brain stem inhibition and 
cardiorespiratory collapse [27].  
Another rare (post)ictal arrhythmia is ventricular tachycardia/ventricular fibrillation (VT/VF). 
So far three cases of postictal VT/VF leading to (near) SUDEP have been reported [8]. All 
VT/VF occurred directly following a convulsive seizure. No cardiac lesions were found in the 
case reports. There may be a publication bias, however, as cases with seizure-triggered 
VT/VF and cardiac lesions may not qualify as SUDEP and thus may be less likely to be 
reported. The mechanism of seizure-induced VT/VF is unclear. Convulsive seizures may exert 
proarrhythmogenic effects by triggering the sympathetic nervous system, as reflected by the 
peak in catecholamines and electrodermal activity [18, 28]. At the same time, convulsive 
seizures may increase cardiac oxygen deprivation by inducing sinus tachycardia [7] and 
respiratory impairment causing hypoxemia [29]. It has also been found that ECG-markers of 
sudden cardiac death such as QTc-lengthening and/or shortening [30, 31], and T-wave 
alternans are more prevalent [23] during and after convulsive seizures. The various factors 
might interact as seizure-related cardiac repolarization abnormalities appeared more 
frequent in seizures with ictal hypoxemia compared to those without [32]. 
Though seizure-induced VT/VF appears to be rare, a prospective community-based study of 
out-of-hospital cardiac arrests due to ECG-documented VT/VF showed that VT/VF risk in 
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those with epilepsy was three times as high as the general population [33]. A further analysis 
of those cases with epilepsy and VT/VF showed that most were not seizure-related, but 
rather occurred in the context of either pre-existing heart disease or as the immediate result 
of an acute myocardial infarction [34]. Pre-existing heart disease was a stronger predictor for 
VT/VF in people with epilepsy than markers of epilepsy severity. In a minority of cases, 
however, VT/VF was unexplained and a diagnosis of (near) SUDEP was established. It thus 
appears that sudden cardiac arrest and SUDEP are partially overlapping disease entities. 
The increased risk of non-seizure related VF/VT episodes in people epilepsy may be 
explained by high cardiovascular comorbidity [3, 35]. People with epilepsy may have a 
propensity for sudden cardiac death as reduced heart rate variability, a measure of cardiac 
sympathovagal balance that is also a risk marker of sudden cardiac death, progressively 
worsens over time in people with refractory, but not in those with well-controlled, epilepsy 
[36]. In addition, other markers of sudden cardiac death such as early repolarization pattern 
and QTc-prolongation are more frequently found in the interictal ECGs of people with 
epilepsy than in those without epilepsy [37]. 
Seizure related 
arrhythmia 
Reported 
in n cases 
Associated 
seizure types 
Reported 
in n cases 
EEG seizure 
onset 
Reported 
in n cases 
SUDEP 
association 
Ictal asystole 103 99% FDS  
1% FAS 
 
97 46% LT  
31% RT 
13% BT 
10% Other  
80 Unlikely 
Postictal 
asystole 
13 85% fbCS  
15% FDS 
13 20% LT 
60% RT 
20% Other  
10 Likely, 
accompanied 
or preceded 
by 
PGES/apnea 
[Ryvlin et al., 
2013] 
Ictal 
bradycardia 
25 100% FDS 
 
8 52% LT  
38% RT  
10% Other 
21 Unlikely 
Ictal AV Block 11  90% FDS  
10% FAS  
10 73% LT  
18% BT  
10% Other 
11 Unlikely 
Postictal AV 
Block 
2 100% fbCS 2 100% RT 1 Unlikely 
Atrial 
Fibrillation 
13  46% GTCS 
46% fbCS 
8% FDS 
13 33% LT 
33% Gen 
33% Non loc 
3 Unlikely 
(Post)ictal 
ventricular 
fibrillation 
3  100% GTCS 3 Insufficient 
data 
0 Probable, but 
in a minority 
of cases 
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Table 1. Reported (post)ictal cardiac arrhythmias. FDS focal dyscognitive seizure; FAS focal 
autonomic seizure; fbCS focal seizure evolving to bilateral convulsive seizure; GTCS generalised tonic 
clonic seizure; LT left temporal; RT right temporal; BT bitemporal; Gen generalised; Non loc non-
localising; PGES postictal generalized EEG suppression; *in people with refractory focal epilepsy 
admitted for a vEEG recording. For more details see van der Lende et al., 2016 [8]. 
 
Another mechanism explaining the association between arrhythmias and epilepsy is a shared 
genetic risk factor. A rapidly increasing number of genes potentially linking epilepsy to 
cardiac arrhythmias has been identified. Here we discuss some relevant examples; starting 
with the genes predominantly known for their cardiac functions and then the ‘epilepsy 
genes’.  
Several genetic ion channel mutations are thought to be expressed in the brain as well as in 
the heart, and might thus cause seizures and cardiac arrhythmias. The first reported genetic 
link between epilepsy and cardiac arrhythmias was the discovery of cardiac sodium channel 
gene SCN5A in the brain [38]. Subsequently, more pathogenic variants in the long QT (LQT) 
gene family (i.e. KCNQ1, KCNH2 and SCN5A) were associated with a “seizure phenotype” 
(e.g. self-reported diagnosis of epilepsy and AED use) [39-44]. Mice models indicated that 
other, non-LQT, cardiac channelopathy genes including RYR2 (associated with 
catecholaminergic polymorphic ventricular tachycardia) [45], and HCN1-4 [46, 47] potentially 
predispose to epilepsy. 
Several postmortem studies suggest that the LQT and non-LQT cardiac gene mutations are 
more common in SUDEP victims [48-50]. As ictal recordings are lacking, it remains 
questionable whether the fatal events were caused by arrhythmias. The same applies to the 
identification of ‘epilepsy genes’ in the post-mortem cohorts [48, 49]. These mutations could 
be markers explaining epilepsy severity or a genetically mediated liability to fatal seizures. In 
certain epilepsy syndromes, SUDEP risk seems particularly high. 
The most recognized example is the Dravet syndrome (DS), a severe epilepsy syndrome with 
high premature mortality, caused by SCN1A mutation [51]. In mutant SCN1A knock-out mice, 
postictal bradycardia and seizure-triggered ventricular fibrillation were recorded before a 
death resembling SUDEP [52, 53]. In DS subjects, markers associated with the risk of sudden 
cardiac death (decreased HRV and increased QT-dispersion) have been found [54, 55]. Ictal 
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proof is, however, lacking and is the subject of an ongoing study (ClinicalTrials.gov Identifier: 
NCT02415686).  
Other less well studied examples of ‘epilepsy genes’ possibly mediating SUDEP risk include 
KCNA1 and SCN8A. KCNA1 is expressed in the vagal nerve as well as in the brain, and is 
associated with seizures, cardiac arrhythmias, vagal hyperexcitability and premature death in 
KCNA1 null mice [56]. Mutations in this gene were found in a SUDEP case with epileptic 
encephalopathy and suspected cardiac arrhythmias [57].  
A novel pathogenic SCN8A mutation was identified through whole-genome sequencing in a 
family affected by epileptic encephalopathy and SUDEP [58]. Before then, SCN8A mutations 
had only been linked to epilepsy in mice [59]. The SCN8A gene encodes a sodium channel 
that is expressed in heart and brain of mice and rats, and plays a role in excitation-
contraction coupling, action potential propagation and pacemaking [60, 61]. 
We previously discussed how seizures may cause arrhythmias. Whether the converse 
phenomenon exists is a subject of controversy. The major complication is the fact that 
syncopal events are easily mistaken for epilepsy. Misdiagnosis of epilepsy is common, with 
reported rates of false positives of up to 71% , and syncope is the most misdiagnosed 
condition [Xu et al., 2016]. Rates of misdiagnosis of epilepsy vary from 23% in a community-
based study of people with a primary diagnosis of epilepsy [62], to 42% in a group of people 
with seemingly refractory epilepsy [63]. Which is understandable as various symptoms and 
signs are seen in both conditions [11, 63-65]. Notably, jerking movements or signs indicative 
of cerebral standstill (complete flattening of the EEG) such as roving eye movements or 
stertorous breathing [11] are often interpreted as signs specific to epilepsy. Consequently, 
most seemingly overlapping presentations turn out not to be an isolated phenomenon of 
either syncope or epilepsy, if a proper investigation is performed (e.g. ictal recording of 
video, heart rate, blood pressure and EEG). Two large scale surveys of up to 2000 tilt-table 
tests failed to identify any adult case with syncopal-induced seizures [66, 67]. In children, 
however, a few cases have been reported with a cardioinhibitory reflex syncope followed by 
video-EEG documented clonic seizures [68-70]. The reason why this phenomenon only 
appears to affect children is unknown. It may be that the seizure threshold is lower in 
children (paralleling febrile seizures that also peak in childhood). Alternatively, the depth of 
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cerebral anoxia may be more profound in children as reflected by prolonged asystolic spells. 
For clinical management it is important to stress that syncope-induced seizures are 
extremely rare and probably only affect children. The diagnosis requires an ictal video-EEG 
recording. 
Several AEDs, particularly those with sodium blocking properties are known to trigger 
conduction abnormalities or arrhythmias [71]. Atrioventricular (AV) conduction is the most 
frequent reported complication. ST changes, Brugada-like patterns, atrial fibrillation and QTc 
prolongation have also been reported but the association with AED treatment is less well 
established [72-86]. Most clinically relevant arrhythmias were related to AED overdose. 
Carbamazepine is, however, known to cause AV conduction blocks at low levels; this is 
almost exclusively reported in elderly women [77, 79, 87]. Rapid administration of phenytoin 
may also cause sinus arrest and hypotension; elderly people and those with pre-existing 
heart disease seem most vulnerable to these adverse effects. IV administration should, 
therefore, be undertaken slowly, with continuous cardiac monitoring [76, 83, 86, 88]. The 
above-mentioned AED effects do not seem to play a role in ictal arrhythmias. Nevertheless, 
it is important to take these effects into consideration in the selection of an AED and to 
monitor adverse effects closely especially in elderly people and those with cardiovascular 
comorbidities (Table 2). 
Putative mechanisms of associations between epilepsy and cardiac arrhythmias 
Mechanisms of association Conditions References  
Causal 
 
 
 
Arrhythmias  Seizures 
 
Battaglia et al., 1989; Horrocks et 
al., 2005; Stephenson et al., 2004 
Shared risk factor 
 
 
Genetics  Epilepsy and arrhythmias 
- Important ‘heart genes’: 
KCNQ1, KCNH2, SCN5A, RYR2  
- Important ‘epilepsy genes’: 
SCN1A, KCNA1, SCN8A 
 
Anderson et al., 2014; Auerbach 
et al., 2013; Auerbach et al., 
2016; Aurlien et al., 2009; Heron 
et al., 2010; Bagnall et al., 2016; 
Benarroch, 2013; Delogu et al., 
2011; Du et al., 2007; Glasscock 
et al., 2010; Goldman et al., 
2016; Hartmann et al., 1999; 
Johnson et al., 2010; Kalume et 
al., 2013; Keller et al., 2009; 
Lehnart et al., 2008; Leu et al., 
2015; Ludwig et al., 2003; 
Noujam et al., 2012; Papale et 
al., 2009; Partemi et al., 2013; 
Postma et al., 2005; Tu et al., 
2011; Veeramah et al., 2012 
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Resultant  
 
 
AED  Arrhythmias 
- Particularly carbamazepine, 
phenytoin and lacosamide 
Al Aloul et al., 2007; El-Menyar 
2011; DeGiorgio et al., 2010; 
DeToledo et al., 2001; Feldman 
and Gidal, 2013; Guldiken et al., 
2016; Ide and Kamijo, 2007; 
Kasarskis et al., 1992; Kaufman 
et al., 2012; Krause et al., 2011; 
Nizam et al., 2011; Randazzo et 
al., 1995; Takayanagi et al., 1998; 
Strimel et al., 2010; Swe et al., 
2016; Zoneraich et al., 1976 
Seizures  Arrhythmias  
- Ictal: tachycardia, asystole, 
bradycardia and AV block.  
- Postictal: asystole, AV block, 
atrial flutter or fibrillation 
and ventricular fibrillation.  
Bardai et al., 2013; Chaila et al., 
2010; Eggleston et al., 2014; Lanz 
et al., 2011; van der Lende et al., 
2016; Sevcencu and Struijk, 2010 
Table 2. Putative mechanisms of associations between epilepsy and cardiac arrhythmias. HRV heart 
rate variability; VT ventricular tachycardia; VF ventricular fibrillation; AED antiepileptic drugs. 
 
EPILEPSY AND STRUCTURAL CARDIAC CONDITIONS  
Epidemiological studies have consistently shown that people with epilepsy have a higher 
prevalence of structural cardiac disease than those without epilepsy [4, 5, 89-92]. 
Cardiovascular disease seems to be a significant contributor to the increased mortality in 
people with epilepsy, compared with the general population [93-95]. 
Shared cardiovascular risk factors can account for the relationship between epilepsy and 
heart disease, in addition to shared genetics and etiological factors. People with a history of 
epilepsy are more likely to be obese, physically inactive, and current smokers [90] and have a 
worse cardiovascular risk profile (i.e. hypertension, hypercholesterolemia, diabetes mellitus, 
stroke/TIA) than the general population [35, 90, 96, 97]. Unsurprisingly, people with epilepsy 
have higher rates of fatal and nonfatal cardio- and cerebrovascular disease than controls 
(mortality ratios up to 5.3 and morbidity ratio up to 7) [35, 98, 99]. The presence of 
cardiovascular disease (e.g. congestive heart failure and cardiac arrhythmias) was also 
associated with higher mortality risk in people with epilepsy [100]. 
Epilepsy treatment can also contribute to a poorer cardiovascular risk profile in epilepsy. Use 
of the enzyme-inducing AEDs phenytoin or carbamazepine may lead to elevated serological 
vascular risk markers (e.g. total cholesterol, LDL, homocysteine), and, thus, result in 
accelerated atherosclerosis [101-104]. Certain AEDs (e.g. valproic acid, carbamazepine) are 
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also known to cause weight gain and increase the risk of developing non-alcoholic fatty liver 
disease and metabolic syndrome, leading to further deterioration of the cardiovascular risk 
profile [102].  
The co-occurrence of epilepsy and (congenital) heart disease, often accompanied by 
intellectual disability, may result from a multiple malformation syndrome: genetic defects 
may affect the development of both heart and brain, or abnormal cardiovascular function 
may lead to poor (intrauterine) brain growth [105]. 
CV disease can sometimes (indirectly) cause epilepsy through a predisposition to stroke 
[106, 107]. Stroke is a common risk factor for epilepsy and accounts for about a third of 
newly diagnosed seizures in people over the age of 60 years [107-110]. In particular, those 
with ischemic events with cortical involvement, cerebral hemorrhage (i.e. primary 
hemorrhage or hemorrhagic transformation of ischemic stroke) and early post-stroke 
seizures, have an increased risk of post-stroke epilepsy [107].  
Seizure activity may not only induce arrhythmias but may also lead to structural cardiac 
changes [71, 111-113]. Epileptic seizures have been reported to provoke cardiac ischaemia 
via both acute and chronic effects on the heart (e.g. impaired heart rate variability, cardiac 
fibrosis, ST-segment depression and increased heart rate) [71, 114]. Transient myocardial 
ischaemia as indicated by ST-segment depression, was reported in a small-scale study in 40% 
of all 15 seizures [114]. Another study, however, failed to demonstrate troponin increases, 
suggesting that the reported ST changes do not usually cause myocardial damage [115]. 
Seizures are the second most frequent CNS condition known to induce the cardiomyopathy 
known as Takotsubo syndrome (TTS) [116]. TTS mimics myocardial infarction clinically, 
electrocardiographically and chemically [117]. It is characterized by acute onset of chest pain 
and dyspnoea, sometimes concomitant with palpitations, tiredness, oedema, fever, syncope, 
anxiety, nausea or vomiting [116]. The seizure type that most frequently causes TTS is the 
generalized tonic-clonic seizure [118, 119]. Seizures most likely trigger TTS by the stress-
induced release of catecholamines [120]. This abundant catecholamine release may be a 
contributing factor in fatal status epilepticus [121]. A relationship between TTS and SUDEP, 
however, does not appear likely [116]. 
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Putative mechanisms of associations between epilepsy and structural cardiac disease 
Mechanisms of association Conditions References 
Causal 
 
 
 
Cardiac conditions, e.g. embolism 
and congenital cardiac 
abnormalities  Stroke  
Attar et al., 2016; Ferlazzo et al., 
2016; Gaitatzis et al. 2004 
Shared risk factor 
 
 
Genetic  Malformation of cortical 
and cardiac development  
 
Shared cardiovascular risk factors 
 Stroke  
Miller and Vogel, 1999 
 
 
Centers for Disease Control and 
Prevention (CDC), 2013; Elliott et 
al., 2008; Gaitatzis et al., 2004; 
Kobau et al., 2008 
Resultant  
 
 
AED  Arteriosclerosis  
 
 
AED  Weight gain, non-alcoholic 
fatty liver disease and metabolic 
syndrome  
 
Seizures  Transient myocardial 
ischaemia 
 
Seizures  Seizure-triggered 
Takotsubo syndrome (TTS)  
Brodie et al., 2013; Katsiki et al., 
2014; LoPinto and Mintzer, 2010; 
Mintzer et al., 2009 
Katsiki et al., 2014  
 
 
 
P-Codrea Tigaran et al., 2005; 
Schuele, 2009 
 
Finsterer and Wahbi, 2014; 
Finsterer and Bersano, 2015; 
Lemke et al., 2008 
Table 3. Putative mechanisms of associations between epilepsy and structural cardiac disease. AED 
antiepileptic drugs; TTS, Takotsubo syndrome. 
FUTURE CONCEPTS 
Significant progress has been made since the publication of Russel’s case history: the 
complex interrelationship between epilepsy and cardiac conditions has been explored widely 
and this review aimed to capture all major discoveries made in this field (Table 2 and 3). 
Many discoveries of coexisting conditions were made by serendipity, and underlying 
mechanisms are yet to be uncovered. Treatment regimens are consequently often 
speculative and lack a personalized approach involving all comorbid conditions. As 
comorbidity gains recognition we now need to become better at noticing these symptom 
patterns. Today a substantial gap still remains between the specialties, but as we are now 
becoming aware of all overlapping syndromes epileptologists will increasingly need to 
improve their cardiac skills. Pattern recognition can be fostered by incorporating validated 
screening instruments and guidelines, aiding the early identification and treatment of 
cardiovascular comorbidity in epilepsy. Concomitantly, a fundamental change in the way 
clinicians think of epilepsy is crucial.  
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Epilepsy will soon be viewed as a collection of individual disorders that share a phenotype of 
an abnormal tendency for unprovoked epileptic seizures. The number of rare epilepsy 
syndromes with cardiac phenotypes will increase substantially. Epilepsy will be seen as a 
symptom-complex, and all comorbidities, even the most inconspicuous, should be 
considered as part of the stratification and phenotyping in people with epilepsy. 
Cardiovascular comorbidities will provide insight into common mechanisms for epilepsy and 
give a window into common genetic predispositions. They may also provide important 
diagnostic clues. Channelopathies, for example, are increasingly identified in people with 
epilepsy. Genetic factors may explain both the epilepsy and the comorbid disorder(s), even 
in people with sporadic epilepsies [122]. Genome wide scanning will be widely available and 
drive the paradigm shift in epilepsy. Certain genes might be identified as contributing to 
SUDEP [48, 49], potentially allowing the development of individualised risk prevention 
strategies. Another major contributor to early identification of overlapping syndromes will 
be the development of new non-invasive tools to record heart function at home. The 
miniaturisation of sensors will favour long-term home-based recordings thus aiding the early 
identification of cardiac arrhythmias. 
Advances in seizure detection will likely take off. ECG alone will help to detect a wide variety 
of seizures but lacks specificity. Combining ECG with other modalities including an 
accelerometry and electrodermal activity will likely improve accuracy and facilitate the 
widespread use of seizure detection devices in those with refractory epilepsy [123, 124].  
Another unmet need relates to the treatment of epilepsy: many AEDs have 
proarrhythmogenic and arteriosclerogenic effects. Though non-pharmacological options 
exist, drug therapy is still the mainstay of epilepsy treatment and other options are usually 
only explored after AEDs have failed to successfully control seizures [125]. Many new AEDs 
have been launched in the last two decades, but have failed to improve the burden of side 
effects or substantially change prognosis for seizure control [126, 127]. With improved 
understanding of epileptogenesis, epigenetic determinants and pharmacogenomics comes 
the hope for better, disease-modifying or even curative pharmacological and non-
pharmacological treatment strategies. Until then, comorbidity should be considered when 
prescribing AEDs. 
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The incorporation of neurocardiology into the paroxysmal spectrum will require a critical 
review of the epilepsy services. We need to validate new instruments to screen for 
cardiovascular conditions. Modern non-invasive long-term ECG devices may help screen for 
cardiac conditions and a cardiologist should review any relevant abnormalities. In cases 
where there is a relevant family history or abnormal ECG findings, a specialist cardiac 
assessment should be done. Identification and adequate treatment of cardiovascular 
disorders in epilepsy should therefore be an important part of epilepsy management.  
Particular attention should be given to modifiable risk factors such as smoking, obesity, 
sedentary lifestyle, high cholesterol and hypertension. Physicians should screen for these 
risk factors in people with epilepsy, provide general health information and if necessary 
adjust AED treatment. Further studies are needed to improve risk profiling, thus allowing for 
screening in high risk individuals (with, for example, implantable loop recorders) and 
targeted interventions (e.g. defibrillators). 
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